Cipla USA acquires anti-infective Zemdri from Achaogen Inc

Drug firm Cipla has said its arm Cipla USA Inc has acquired prescription drug Zemdri, used for the treatment of complicated urinary tract infections, from Achaogen Inc. Cipla USA has acquired worldwide rights of Zemdri, excluding Greater China, with its allied assets and limited liabilities, Cipla said in a late night regulatory filing on Wednesday. "The acquisition of Zemdri deepens our pipeline of specialty products in the US in our identified focus areas of central nervous system, lung delivery of medicines, and institutionally administered products," Cipla MD and Global CEO Umang Vohra said. Zemdri is a once-daily novel intravenous (IV) aminoglycoside for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults who are unresponsive to currently available treatment options, Cipla said.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!